Lit Matters 3: IV Sodium valproate for migraines?

Acute migraine in the emergency department is still a first-line NSAID problem, but IV sodium valproate may be a reasonable option for migraine without aura when usual therapies are limited. The key caution is external validity: this trial excluded secondary headache and patients with aura.

IV Migraine Therapy Evidence

• First-line NSAID framing: NSAIDs remain preferred first-line acute migraine therapy per headache guidelines, with ibuprofen a familiar benchmark because it reduces prostaglandin-mediated perivascular nociceptor activation.
• Valproate clinical niche: IV sodium valproate appears safe and likely effective for migraine without aura, making it a practical alternative when standard migraine regimens are unsuitable or have already failed.
• Head-to-head trial signal: In this randomized double-blind ED study, 800 mg IV sodium valproate beat 800 mg IV ibuprofen on the primary endpoint of at least 50% pain reduction from baseline.
• Recurrence and rescue use: Rescue analgesia and 48-hour headache recurrence were not statistically different between groups, but the recurrence pattern raises a few practice-level questions we get into in the episode.
• Applicability limits: The findings apply to adults with migraine without aura, not suspected secondary headache, pregnancy, recent analgesic use, or patients already taking valproate for seizures.
• Placebo effect concern: No placebo arm leaves an important uncertainty in a symptom-driven condition like migraine, where receiving any active IV treatment can meaningfully shift reported pain scores.